These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18243718)

  • 21. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis.
    Kumar Y; Gurusamy K; Pamecha V; Davidson BR
    Pancreas; 2007 Aug; 35(2):114-9. PubMed ID: 17632316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
    Lüftner D; Mesterharm J; Akrivakis C; Geppert R; Petrides PE; Wernecke KD; Possinger K
    Anticancer Res; 2000; 20(6D):5077-82. PubMed ID: 11326672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
    Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
    J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
    Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
    Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concomitant analysis of salivary tumor markers--a new diagnostic tool for oral cancer.
    Nagler R; Bahar G; Shpitzer T; Feinmesser R
    Clin Cancer Res; 2006 Jul; 12(13):3979-84. PubMed ID: 16818695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzyme Kinetic Assay to Measure the Activity of Tumor M2 Pyruvate Kinase in Breast Cancer Patients.
    Guan M; Tong Y; Liu X; Dong D; Zhou Y
    Ann Clin Lab Sci; 2017 Nov; 47(6):676-686. PubMed ID: 29263041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative detection of tumor M2-PK in serum and plasma.
    Hugo F; Fischer G; Eigenbrodt E
    Anticancer Res; 1999; 19(4A):2753-7. PubMed ID: 10470235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma TM2-PK levels in mycosis fungoides patients.
    Hapa A; Erkin G; Hasçelik G; Pektaş D; Arslan U
    Arch Dermatol Res; 2011 Jan; 303(1):35-40. PubMed ID: 20927531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
    Goonetilleke KS; Mason JM; Siriwardana P; King NK; France MW; Siriwardena AK
    Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A.
    Pezzilli R; Migliori M; Morselli-Labate AM; Campana D; Ventrucci M; Tomassetti P; Corinaldesi R
    Anticancer Res; 2003; 23(3C):2969-72. PubMed ID: 12926146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
    Oremek GM; Sapoutzis N; Kramer W; Bickeböller R; Jonas D
    Anticancer Res; 2000; 20(6D):5095-8. PubMed ID: 11326675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
    Schneider J; Bitterlich N; Schulze G
    Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages.
    Jou YJ; Lin CD; Lai CH; Tang CH; Huang SH; Tsai MH; Chen SY; Kao JY; Lin CW
    Clin Chim Acta; 2011 Jul; 412(15-16):1357-65. PubMed ID: 21497587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
    Li YG; Zhang N
    Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker?
    Varga Z; Hegele A; Stief T; Heidenreich A; Hofmann R
    Urol Res; 2002 May; 30(2):122-5. PubMed ID: 12086017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
    Oremek GM; Gerstmeier F; Sauer-Eppel H; Sapoutzis N; Wechsel HW
    Anticancer Res; 2003; 23(2A):1127-30. PubMed ID: 12820359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma.
    Roigas J; Deger S; Schroeder J; Wille A; Turk I; Brux B; Jung K; Schnorr D; Loening SA
    Urol Res; 2003 Dec; 31(6):358-62. PubMed ID: 14513300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring.
    Schneider J; Neu K; Grimm H; Velcovsky HG; Weisse G; Eigenbrodt E
    Anticancer Res; 2002; 22(1A):311-8. PubMed ID: 12017309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.